EE200200631A - Vesisuspensioonipõhine parenteraalne ravimpreparaat stabiliseeritud pH väärtusega ning L-metioniinikasutamine selle valmistamiseks - Google Patents

Vesisuspensioonipõhine parenteraalne ravimpreparaat stabiliseeritud pH väärtusega ning L-metioniinikasutamine selle valmistamiseks

Info

Publication number
EE200200631A
EE200200631A EEP200200631A EEP200200631A EE200200631A EE 200200631 A EE200200631 A EE 200200631A EE P200200631 A EEP200200631 A EE P200200631A EE P200200631 A EEP200200631 A EE P200200631A EE 200200631 A EE200200631 A EE 200200631A
Authority
EE
Estonia
Prior art keywords
preparation
methionine
stabilized
water
parenteral pharmaceutical
Prior art date
Application number
EEP200200631A
Other languages
English (en)
Inventor
Colombo Giuseppe
Martini Alessandro
E. Fox Lloyd
Original Assignee
Pharmacia Italia S.P.A.
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A., Pharmacia & Upjohn Company filed Critical Pharmacia Italia S.P.A.
Publication of EE200200631A publication Critical patent/EE200200631A/et
Publication of EE05376B1 publication Critical patent/EE05376B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EEP200200631A 2000-05-15 2001-04-25 Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal EE05376B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/571,395 US6495534B2 (en) 2000-05-15 2000-05-15 Stabilized aqueous suspensions for parenteral use
PCT/EP2001/004643 WO2001087266A1 (en) 2000-05-15 2001-04-25 Stabilized aqueous suspensions for parenteral use

Publications (2)

Publication Number Publication Date
EE200200631A true EE200200631A (et) 2004-04-15
EE05376B1 EE05376B1 (et) 2011-02-15

Family

ID=24283530

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200631A EE05376B1 (et) 2000-05-15 2001-04-25 Vesisuspensioonip?hineÁparenteraalneÁravimpreparaatÁjaÁsedaÁsisaldavÁviaal

Country Status (30)

Country Link
US (3) US6495534B2 (et)
EP (1) EP1282402B1 (et)
JP (1) JP4205341B2 (et)
KR (1) KR100828957B1 (et)
CN (1) CN100473376C (et)
AR (3) AR029924A1 (et)
AT (1) ATE313316T1 (et)
AU (2) AU2001267371B2 (et)
BR (1) BR0110841A (et)
CA (1) CA2409059C (et)
CZ (1) CZ303872B6 (et)
DE (1) DE60116084T2 (et)
DK (1) DK1282402T3 (et)
EA (1) EA007682B1 (et)
EE (1) EE05376B1 (et)
ES (1) ES2254443T3 (et)
HK (1) HK1054194B (et)
HU (1) HU229800B1 (et)
IL (2) IL152537A (et)
IN (1) IN224279B (et)
MX (1) MXPA02011195A (et)
NO (1) NO332215B1 (et)
NZ (1) NZ522324A (et)
PE (1) PE20011322A1 (et)
PL (1) PL203075B1 (et)
SI (1) SI1282402T1 (et)
SK (1) SK287641B6 (et)
TW (1) TWI256310B (et)
WO (1) WO2001087266A1 (et)
ZA (1) ZA200208738B (et)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use
US7482116B2 (en) 2002-06-07 2009-01-27 Dna Genotek Inc. Compositions and methods for obtaining nucleic acids from sputum
WO2004018312A1 (en) 2002-08-21 2004-03-04 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
BRPI0408925A (pt) * 2003-03-31 2006-04-04 Alza Corp veìculos de fase simples não-aquosos e formulações utilizando tais veìculos
US9532995B2 (en) * 2003-09-03 2017-01-03 Miscon Trading S.A. Methods for the treatment of endometriosis
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
CA2581076A1 (en) * 2004-09-14 2006-03-23 Molecular Therapeutics, Inc. D-methionine formulation with improved biopharmaceutical properties
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
WO2007095341A2 (en) * 2006-02-15 2007-08-23 Tika Läkemedel Ab Sterilization of corticosteroids with reduced mass loss
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
JP5371180B2 (ja) * 2006-06-15 2013-12-18 日立コンシューマエレクトロニクス株式会社 投写型映像表示装置
US7687516B2 (en) * 2006-09-27 2010-03-30 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
CA2669727C (en) * 2006-09-27 2014-10-28 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
US20100076019A1 (en) * 2006-10-11 2010-03-25 Eagle Pharmaceuticals, Inc. Alcohol free formulation of argatroban
GB0625962D0 (en) * 2006-12-23 2007-02-07 Renovo Ltd Medicaments and methods for wound healing
US20090258850A1 (en) * 2007-08-21 2009-10-15 Frincke James M Stabilized therapeutic compositions and formulations
US8287729B2 (en) * 2008-04-28 2012-10-16 California Polytechnic Corporation Field water purification system
GB0813628D0 (en) * 2008-07-25 2008-09-03 Arrow Int Ltd Stable coated anti-cancer agent
UY33103A (es) * 2009-12-15 2011-07-29 Techsphere S A De C V Formulacion farmaceutica parenteral en suspension, de liberacion sostenida, en dosis baja y ultra baja, en terapia hormonal en el sindrome climaterico
EP3150702B1 (en) 2011-06-19 2021-05-19 DNA Genotek, Inc. Devices, solutions and methods for sample collection
RS62297B1 (sr) 2011-11-23 2021-09-30 Therapeuticsmd Inc Prirodne kombinovane hormonske supstitucione formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA74095U (ru) * 2012-07-20 2012-10-10 Николай Иванович Гуменюк Препарат для лечения туберкулеза
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3046544A4 (en) 2013-09-17 2017-03-22 Terapio Corporation Methods of preventing or treating mucositis using rlip76
CN104706578B (zh) * 2013-12-14 2019-04-23 天津金耀集团有限公司 一种醋酸甲泼尼龙混悬注射液组合物的制备方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US9907449B2 (en) 2015-03-16 2018-03-06 Irobot Corporation Autonomous floor cleaning with a removable pad
US9265396B1 (en) 2015-03-16 2016-02-23 Irobot Corporation Autonomous floor cleaning with removable pad
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017149492A1 (en) 2016-03-02 2017-09-08 Teva Pharmaceutical Industries Ltd. Medroxyprogesterone acetate injectable compositions and methods of use
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
US11590077B2 (en) * 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
WO2019012100A1 (en) 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
WO2019048906A1 (en) * 2017-09-07 2019-03-14 Teva Pharmaceutical Industries Ltd. INJECTABLE COMPOSITIONS OF MEDROXYPROGESTERONE ACETATE AND METHODS OF USE
MX2020002606A (es) * 2017-09-07 2020-10-05 Teva Pharma Composiciones inyectables de acetato de medroxiprogesterona y metodos de uso.
JP7220712B2 (ja) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク． フルベストラント製剤とその使用方法
EP3737380A4 (en) * 2018-01-11 2021-09-29 Meritage Pharma, Inc. STABLE CORTICOSTEROID COMPOSITIONS
AU2019334932B2 (en) 2018-09-07 2025-01-30 Family Health International D/B/A Fhi 360 Medroxyprogesterone acetate injectable compositions and methods of use
US10544923B1 (en) 2018-11-06 2020-01-28 Verifone, Inc. Devices and methods for optical-based tamper detection using variable light characteristics
WO2020106891A1 (en) 2018-11-20 2020-05-28 Spectrum Solutions, Llc Sample collection system including sealing cap and valve
IT201900002857A1 (it) 2019-02-27 2020-08-27 Ntc S R L Procedimento di riempimento di contenitori con una polvere
US11701094B2 (en) 2019-06-20 2023-07-18 Spectrum Solutions L.L.C. Sample collection system including valve and plug assemblies
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
WO2022245939A1 (en) * 2021-05-19 2022-11-24 Acies Medical Llc Point-of-use calibration system for iron ion detection system

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2861920A (en) * 1954-05-04 1958-11-25 Upjohn Co Therapeutic suspensions of steroids containing pvp and/or pva
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
US4038389A (en) * 1975-05-07 1977-07-26 The Upjohn Company Medroxyprogesterone acetate compositions
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
JP2577744B2 (ja) 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
DK0431663T3 (da) 1989-12-06 1994-03-07 Akzo Nobel Nv Stabiliserende opløsninger af psykotrope midler
JPH0597671A (ja) 1991-10-04 1993-04-20 Sumitomo Pharmaceut Co Ltd 注射用凍結乾燥製剤
CA2120197A1 (en) 1993-04-02 1994-10-03 Kenji Endo Stable aqueous dispersions containing liposomes
JP3862295B2 (ja) * 1993-09-30 2006-12-27 独立行政法人理化学研究所 抗肥満剤
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
JP3543144B2 (ja) 1995-03-11 2004-07-14 国際試薬株式会社 臨床検査用製剤
US5780431A (en) 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
JP2001501619A (ja) 1996-10-04 2001-02-06 アムジェン インコーポレーテッド ｍｐｌリガンドを含有する医薬組成物
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
JP3748970B2 (ja) 1997-01-31 2006-02-22 電気化学工業株式会社 ヒアルロン酸ナトリウム含有水溶液
KR100508227B1 (ko) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US5968918A (en) * 1997-10-17 1999-10-19 Kanda; Iwao Method for the prevention of coronary artery spasm
US5972921A (en) * 1997-12-12 1999-10-26 Hormos Medical Oy Ltd. Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men
DK1067934T3 (da) 1998-04-02 2004-03-29 Akzo Nobel Nv Flydende oral opløsning omfattende det anti-depressive middel mirtazapin
CN1245216C (zh) 1999-10-04 2006-03-15 希龙公司 稳定化的含多肽的液体药物组合物
US6495534B2 (en) * 2000-05-15 2002-12-17 Pharmacia & Upjohn Spa Stabilized aqueous suspensions for parenteral use

Also Published As

Publication number Publication date
BR0110841A (pt) 2003-03-11
DE60116084T2 (de) 2006-08-17
DK1282402T3 (da) 2006-05-08
IL165888A0 (en) 2006-01-15
KR100828957B1 (ko) 2008-05-13
ZA200208738B (en) 2003-10-29
AR098830A2 (es) 2016-06-15
NO20025431L (no) 2003-01-13
MXPA02011195A (es) 2003-03-10
US20030130245A1 (en) 2003-07-10
NZ522324A (en) 2005-02-25
EA200201208A1 (ru) 2003-04-24
CZ303872B6 (cs) 2013-06-05
CA2409059A1 (en) 2001-11-22
CN1429101A (zh) 2003-07-09
KR20030020280A (ko) 2003-03-08
SK287641B6 (sk) 2011-05-06
EA007682B1 (ru) 2006-12-29
EE05376B1 (et) 2011-02-15
EP1282402B1 (en) 2005-12-21
AU6737101A (en) 2001-11-26
TWI256310B (en) 2006-06-11
EP1282402A1 (en) 2003-02-12
NO20025431D0 (no) 2002-11-13
IL152537A0 (en) 2003-05-29
HK1054194A1 (zh) 2003-11-21
SI1282402T1 (sl) 2006-04-30
PL203075B1 (pl) 2009-08-31
AR029924A1 (es) 2003-07-23
ATE313316T1 (de) 2006-01-15
PL365793A1 (en) 2005-01-10
PE20011322A1 (es) 2002-01-10
US20020115645A1 (en) 2002-08-22
HUP0302021A2 (hu) 2003-09-29
CA2409059C (en) 2006-04-18
AU2001267371B2 (en) 2006-01-05
CZ20023750A3 (cs) 2003-03-12
DE60116084D1 (de) 2006-01-26
IN224279B (et) 2005-02-25
SK15982002A3 (sk) 2003-05-02
ES2254443T3 (es) 2006-06-16
HU229800B1 (en) 2014-07-28
US20030114430A1 (en) 2003-06-19
CN100473376C (zh) 2009-04-01
JP2003533467A (ja) 2003-11-11
JP4205341B2 (ja) 2009-01-07
AR111695A2 (es) 2019-08-07
HUP0302021A3 (en) 2011-03-28
HK1054194B (zh) 2010-02-12
WO2001087266A1 (en) 2001-11-22
NO332215B1 (no) 2012-07-30
US6495534B2 (en) 2002-12-17
IL152537A (en) 2007-06-17

Similar Documents

Publication Publication Date Title
CR8037A (es) Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
EE05387B1 (et) KinasoliiniÁderivaadid,ÁnendeÁvalmistamismeetodÁjaÁkasutamine
IL151045A0 (en) 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
GB2406523B (en) Improvements in and relating to the formation of knots
IL153246A0 (en) Substituted quinazoline derivatives and their use as inhibitors
IL228034A0 (en) Formulations with a high concentration of antibodies and proteins
AR028027A1 (es) Componente de compuestos en secciones y procedimiento para producir el mismo
NO20013332L (no) Frac-plugg med kulehylse
NO20025872D0 (no) Forbindelse med koniske gjenger
SI1499589T1 (sl) Derivati N-(fenil(piperidin-2-il)metil)benzamida,njihova priprava in njihova terapevtska uporaba
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
HUP0300917A3 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and pharmaceutical compositions containing them
AU1334602A (en) Osteopontin-coated surfaces and methods of use
AU2003251047A8 (en) Use of quinoline derivatives with anti-integrase effect and applications thereof
AR028198A1 (es) Variantes de pululanasa y metodos para preparar dichas variantes con propiedades predeterminadas
EE200300044A (et) Vasoprotektiivse ja antioksüdantse toimega preparaat ning selle kasutamine
GB0119497D0 (en) Expression of modified antibodies in avian cells
GB0116489D0 (en) Improvements in and relating to consumption of content
EP1668464A4 (en) USE OF TRANSFORMATION TECHNOLOGY TO PRODUCE SEMANTIC DESCRIPTIONS
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
GB2390543B (en) Improvements in and relating to the administration of copper to an animal
PL357906A1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
DE602005026869D1 (de) Interferonproteinmutanten und deren anwendung
SI1280522T1 (en) Combination of carboxyalkylethers with antihypertensives and pharmaceutical use
GB0328255D0 (en) Quinazoline derivatives and their uses

Legal Events

Date Code Title Description
GB1A Change in the ownership or in the address of the owner